Photochemical internalisation in drug and gene delivery

Advanced Drug Delivery Reviews

Volumn 56, Issue 1, 2004, Pages 95-115

  Høgset, Anders ^a   Prasmickaite, Lina ^b   Selbo, Pål K ^b   Hellum, Marit ^b   Engesæter, Birgit Ø ^b   Bonsted, Anette ^b   Berg, Kristian ^b  

^a PCI Biotech AS   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Drug delivery; Endosomal release; Gene therapy; Light induced; Oligonucleotide delivery; Photosensitiser; Protein therapy; Site specific

Indexed keywords

BIODEGRADATION; BIOLOGICAL MEMBRANES; GENES; MOLECULAR WEIGHT; PHOTOSENSITIZERS; PROTEINS;

PHOTOCHEMICAL INTERNALIZATION (PCI);

DRUG PRODUCTS;

AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; BLEOMYCIN; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; GELONIN; INTERLEUKIN 12; OLIGONUCLEOTIDE; PEPTIDE; PEPTIDE NUCLEIC ACID; PHOTOSENSITIZING AGENT; PHTHALOCYANINE ALUMINUM; PHTHALOCYANINE DERIVATIVE; POLYETHYLENEIMINE; POLYLYSINE; PORPHYRIN DERIVATIVE; PROTOPORPHYRIN; TETRAKIS(3 HYDROXYPHENYL)PORPHYRIN; TETRAPHENYLPORPHINESULFONIC ACID; TRANSFERRIN; UNCLASSIFIED DRUG;

CELL LINE; CYTOTOXICITY; DEVICE; DOSE RESPONSE; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE DELIVERY SYSTEM; HUMAN; ILLUMINATION; IN VITRO STUDY; INTERNALIZATION; LYSOSOME; MACROMOLECULE; MEDICAL TECHNOLOGY; MOLECULAR WEIGHT; NONHUMAN; PHOTOCHEMICAL INTERNALIZATION; PHOTOCHEMISTRY; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; REVIEW; TECHNOLOGY;

EID: 0346729779     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2003.08.016     Document Type: Article

References (95)

1. Dougherty T.J., Gomer C.J., Henderson B.W., Jori G., Kessel D., Korbelik M., Moan J., Peng Q. Photodynamic therapy. J. Natl. Cancer Inst. 90:1998;889-905.
2. Pass H.I. Photodynamic therapy in oncology: mechanisms and clinical use. J. Natl. Cancer Inst. 85:1993;443-456.
3. Moan J., Sommer S. Oxygen dependence of the photosensitizing effect of hematoporphyrin derivative in NHIK 3025 cells. Cancer Res. 45:1985;1608-1610.
4. Weishaupt K.R., Gomer C.J., Dougherty T.J. Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res. 36:1976;2326-2329.
5. Henderson B., Dougherty T.J. How does photodynamic therapy work? Photochem. Photobiol. 55:1992;145-157.
6. Kochevar I.E., Redmond R.W. Photosensitized production of singlet oxygen. Methods Enzymol. 319:2000;20-28.
7. Moan J., Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem. Photobiol. 53:1991;549-553.
8. Jori G., Spikes J.D. Photobiochemistry of porphyrins. Smith K.C. Topics in Photomedicine. 1984;183-318 Plenum, New York.
9. Moan J., Berg K. Photochemotherapy of cancer: experimental research. Photochem. Photobiol. 55:1992;931-948.
10. LaMuraglia G.M., Schiereck J., Heckenkamp J., Nigri G., Waterman P., Leszczynski D., Kossodo S. Photodynamic therapy induces apoptosis in intimal hyperplastic arteries. Am. J. Pathol. 157:2000;867-875.
11. Neave V., Gianotta S., Hyman S., Schneider J. Hematoporphyrin uptake in atherosclerotic plaques: therapeutic potentials. Neurosurgery. 23:1988;307-312.
12. Ortu P., LaMuraglia G.M., Roberts W.G., Flotte T.J., Hasan T. Photodynamic therapy of arteries. A novel approach for treatment of experimental intimal hyperplasia. Circulation. 85:1992;1189-1196.
13. Rockson S.G., Kramer P., Razavi M., Szuba A., Filardo S., Fitzgerald P., Cooke J.P., Yousuf S., DeVault A.R., Renschler M.F., Adelman D.C. Photoangioplasty for human peripheral atherosclerosis. Results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin). Circulation. 102:2000;2322-2324.
14. Ben-Hur E., Moor A.C., Margolis-Nunno H., Gottlieb P., Zuk M.M., Lustigman S., Horowitz B., Brand A., Van Steveninck J., Dubbelman T.M. The photodecontamination of cellular blood components: mechanisms and use of photosensitization in transfusion medicine. Transfus. Med. Rev. 10:1996;15-22.
15. Matthews J.L., Newman J.T., Sogandares-Bernal F., Judy M.M., Skiles H., Leveson J.E., Marengo-Rowe A.J., Chanh T.C. Photodynamic therapy of viral contaminants with potential for blood banking applications. Transfusion. 28:1988;81-83.
16. van Moor A.C., Dubbelman T.M., Van Steveninck J., Brand A. Photodynamic sterilization of red cells and its effect on contaminating white cells: viability and mechanism of cell death. Transfusion. 39:1999;599-607.
17. Ratkay L.G., Chowdhary R.K., Neyndorff H.C., Tonzetich J., Waterfield J.D., Levy J.G. Photodynamic therapy: a comparison with other immunomodulatory treatments of adjuvant-enhanced arthritis in MRL-lpr mice. Clin. Exp. Immunol. 95:1994;373-377.
18. Ratkay L.G., Chowdhary R.K., Iamaroon A., Richter A.M., Neyndorff H.C., Keystone E.C., Waterfield J.D., Levy J.G. Amelioration of antigen-induced arthritis in rabbits by induction of apoptosis of inflammatory cells with local application of transdermal photodynamic therapy. Arthritis Rheum. 41:1998;525-534.
19. Trauner K.B., Hasan T. Photodynamic treatment of rheumatoid and inflammatory arthritis. Photochem. Photobiol. 64:1996;740-750.
20. Boehncke W.H., Konig K., Kaufmann R., Scheffold W., Prummer O., Sterry W. Photodynamic therapy in psoriasis: suppression of cytokine production in vitro and recording of fluorescence modification during treatment in vivo. Arch. Dermatol. Res. 286:1994;300-303.
21. Robinson D.J., Collins P., Stringer M.R., Vernon D.I., Stables G.I., Brown S.B., Sheehan-Dare R.A. Improved response of plaque psoriasis after multiple treatments with topical 5-aminolaevulinic acid photodynamic therapy. Acta Derm.-Venereol. 79:1999;451-455.
22. Donati G., Kapetanios A.D., Pournaras C.J. Principles of treatment of choroidal neovascularization with photodynamic therapy in age-related macular degeneration. Semin. Thromb. Hemost. 14:1999;2-10.
23. Regillo C.D. Update on photodynamic therapy. Curr. Opin. Ophthalmol. 11:2000;166-170.
24. Schmidt-Erfurth U., Hasan T. Mechanism of action of photodynamic therapy with Verteporfin for the treatment of age-related macular degeneration. Surv. Ophthalmol. 45:2000;195-214.
25. Berg K., Bommer J.C., Winkelman J.W., Moan J. Cellular uptake and relative efficiency in cell inactivation by photoactivated sulfonated meso-tetraphenylporphines. Photochem. Photobiol. 52:1990;775-781.
26. Rosenkranz A.A., Jans D.A., Sobolev A.S. Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency. Immunol. Cell Biol. 78:2000;452-464.
27. Moan J., Berg K., Kvam E., Western A., Malik Z., Ruck A., Schneckenburger H. Intracellular localization of photosensitizers. Ciba Found. Symp. 146:1989;95-107.
28. Berg K., Western A., Bommer J.C., Moan J. Intracellular localization of sulfonated meso-tetraphenylporphines in a human carcinoma cell line. Photochem. Photobiol. 52:1990;481-487.
29. Prasmickaite L., Høgset A., Berg K. Evaluation of different photosensitizers for use in photochemical gene transfection. Photochem. Photobiol. 73:2001;388-395.
30. Berg K., Moan J. Lysosomes as photochemical targets. Int. J. Cancer. 59:1994;814-822.
31. Maman N., Dhami S., Phillips D., Brault D. Kinetic and equilibrium studies of incorporation of di-sulfonated aluminum phthalocyanine into unilamellar vesicles. Biochim. Biophys. Acta. 1420:1999;168-178.
32. Moan J., Berg K., Anholt H., Madslien K. Sulfonated aluminium phthalocyanines as sensitizers for photochemotherapy. Effects of small light doses on localization, dye fluorescence and photosensitivity in V79 cells. Int. J. Cancer. 58:1994;865-870.
33. Berg K., Selbo P.K., Prasmickaite L., Tjelle T.E., Sandvig K., Moan J., Gaudernack G., Fodstad Ø., Kjølsrud S., Anholt H., Rodal G.H., Rodal S.K., Høgset A. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res. 59:1999;1180-1183.
34. Berg K., Sandvig K., Moan J. Transfer of Molecules into the Cytosol of Cells. 1996;Patent. PCT/NO95/00149.
35. Prasmickaite L., Høgset A., Berg K. Methods for photochemical transfection: light-induced, site-directed gene delivery. Morgan J.R. Meth. Mol. Med. Gene Therapy Protocols. vol. 69:2001;123-135 Humana Press, Totowa.
36. Belzacq A.-S., Jacotot E., Vieira H.L.A., Mistro D., Granville D.J., Xie Z., Reed J.C., Kroemer G., Brenner C. Apoptosis induction by the photosensitiser verteporfin: identification of mitochondrial adenine nucleotide translocator as a critical target. Cancer Res. 61:2001;1260-1264.
37. Zavodnik I.B., Zavodnik L.B., Bryszewska M.J. The mechanism of Zn-phthalocyanine photosensitised lysis of human erythrocytes. J. Photochem. Photobiol., B Biol. 76:2002;1-10.
38. Prasmickaite L., Høgset A., Selbo P.K., Engesæter B.Ø., Hellum M., Berg K. Photochemical disruption of endocytic vesicles before delivery of drugs: a new strategy for cancer therapy. Br. J. Cancer. 86:2002;652-657.
39. Selbo P.K., Sandvig K., Kirveliene V., Berg K. Release of gelonin from endosomes and lysosomes to cytosol by photochemical internalization. Biochim. Biophys. Acta. 1475:2000;307-313.
40. Selbo P.K., Sivam G., Fodstad Ø., Sandvig K., Berg K. Photochemical internalisation increases the cytotoxic effect of the immunotoxin MOC31-gelonin. Int. J. Cancer. 87:2000;853-859.
41. Høgset A., Prasmickaite L., Tjelle T.E., Berg K. Photochemical transfection: a new technology for light-induced, site-directed gene delivery. Hum. Gene Ther. 11:2000;869-880.
42. Høgset A., Prasmickaite L., Hellum M., Engesæter B.Ø., Olsen V.M., Tjelle T.E., Wheeler C.J., Berg K. Photochemical transfection; a technology for efficient light directed gene delivery. Somat. Cell Mol. Genet. 27:2002;97-113.
43. Prasmickaite L., Høgset A., Tjelle T.E., Olsen V.M., Berg K. The role of endosomes in gene transfection mediated by photochemical internalisation. J. Gene Med. 2:2000;477-488.
44. Høgset A., Engesæter B.Ø., Prasmickaite L., Berg K., Fodstad Ø., Mælandsmo G.M. Light-induced adenovirus gene transfer, an efficient and specific gene delivery technology for cancer gene therapy. Cancer Gene Ther. 9:2002;365-371.
45. Rosenthal I. Phthalocyanines as photodynamic sensitizers. Photochem. Photobiol. 53:1991;859-870.
46. Sharman W.M., Allen C.M., Van Lier J.E. Role of activated oxygen species in photodynamic therapy. Methods Enzymol. 319:2000;376-400.
47. Peng Q., Moan J. Correlation of distribution of sulphonated aluminium phthalocyanines with their photodynamic effect in tumour and skin of mice bearing CaD2 mammary carcinoma. Br. J. Cancer. 72:1995;565-574.
48. Barbieri L., Batelli M.G., Stirpe F. Ribosome-inactivating proteins from plants. Biochim. Biophys. Acta. 1154:1993;237-282.
49. Stirpe F., Olsnes S., Pihl A. Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with cancanavalin A. J. Biol. Chem. 255:1980;6947-6953.
50. Endo Y., Tsurugi K., Lambert J.M. The site of action of six different ribosome-inactivating proteins from plants on eukaryotic ribosomes: the RNA N-glycosidase activity of the proteins. Biochem. Biophys. Res. Commun. 150:1988;1032-1036.
51. Barbieri L., Stirpe F. Ribosome-inactivating proteins from plants: properties and possible uses. Cancer Surv. 1:1982;502-509.
52. Scott C.F. Jr., Lambert J.M., Goldmacher V.S., Blattler W.A., Sobel R., Schlossman S.F., Benacerraf B. The pharmacokinetics and toxicity of murine monoclonal antibodies and gelonin conjugates of these antibodies. Int. J. Immunopharmacol. 9:1987;211-225.
53. Madan S., Ghosh P.C. Interaction of gelonin with macrophages: effect of lysosomotropic amines. Exp. Cell Res. 198:1992;52-58.
54. Wu M. Enhancement of immunotoxin activity using chemical and biological reagents. Br. J. Cancer. 75:1997;1347-1355.
55. McGrath M.S., Rosenblum M.G., Phillips M.R., Scheinberg D.A. Immunotoxin resistance in multidrug resistant cells. Cancer Res. 63:2003;72-79.
56. De Leij L., Berendsen H., Spakman H., The T.H. Proceedings of the first international workshop on small-cell lung-cancer antigens. Lung Cancer. 4:1988;1-114.
57. Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem. 8:2001;1505-1511.
58. Hill S.R., Bobjouklian R., Powis G., Abraham R.T., Ashendel C.L., Zalkow L.H. A multisample assay for inhibitors of phosphatidylinosito phospholipase C: identification of naturally occurring peptide inhibitors with antiproliferative activity. Anti-cancer Drug Des. 9:1994;353-361.
59. Mir L.M., Tounekti O., Orlowski S. Bleomycin: revival of an old drug. Gen. Pharmacol. 27:1996;745-748.
60. Yip Y.L., Ward R.L. Application of phage display technology to cancer research. Curr. Pharm. Biotechnol. 3:2002;29-43.
61. Nixon A.F. Phage display as a tool for protease ligand discovery. Curr. Pharm. Biotechnol. 3:2002;1-12.
62. Jansen B., Zangemeister-Wittke U. Antisense therapy of cancer - the time of truth. Lancet Oncol. 3:2001;672-683.
63. Agrawal S., Kandimalla E.R. Antisense and/or immunostimulatory oligonucleotide therapeutics. Curr. Cancer Drug Targets. 1:2001;197-209.
64. Opalinska J.B., Gewirtz A.M. Nucleic-acid therapeutics: acid principles and recent applications. Nat. Rev., Drug Discov. 1:2002;503-514.
65. Cerchia L., Hamm J., Libri D., Tavitian B., de Franciscis V. Nucleic acid aptamers in cancer medicine. FEBS Lett. 528:2002;12-16.
66. Jaaskelainen I., Urtti A. Cell membranes as barriers for the use of antisense therapeutic agents. Mini-rev. Med. Chem. 2:2002;307-318.
67. Pron G., Mahrour N., Orlowski S., Tounekti O., Poddevin B., Belehradek J. Jr., Mir L.M. Internalisation of the bleomycin molecules responsible for bleomycin toxicity: a receptor-mediated endocytosis mechanism. Biochem. Pharmacol. 57:1998;45-56.
68. Mountain A. Gene therapy: the first decade. Trends Biotechnol. 18:2000;119-128.
69. Somia N., Verma I. Gene therapy: trials and tribulations. Nat. Rev., Genet. 1:2000;91-99.
70. Fischer A. Gene therapy: some results, many problems to solve. Cell Mol. Biol. (Noisy-Le-Grand). 47:2001;1269-1275.
71. Khuri F.R., Nemunaitis J., Ganly I., Arseneau J., Tannock I.F., Romel L., Gore M., Ironside J., MacDougall R.H., Heise C., Randlev B., Gillenwater A.M., Bruso P., Kaye S.B., Hong W.K., Kirn D.H. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6:2000;879-885.
72. Fischer A., Hacein-Bey S., Cavazzana-Calvo M. Gene therapy of severe combined immunodeficiencies. Nat. Rev., Immunol. 2:2002;615-621.
73. Høgset A., Prasmickaite L., Engesæter B.Ø., Hellum M., Selbo P.K., Olsen V.M., Mælandsmo G.M., Berg K. Light directed gene transfer by photochemical internalisation. Curr. Gene Ther. 3:2003;89-112.
74. Hellum M., Høgset A., Engesæter B.Ø., Prasmickaite L., Stokke T., Wheeler C.J., Berg K. Photochemically enhanced gene delivery with cationic lipid/DNA complexes-time course of intracellular events during transfection. Photochem. Photobiol. Sci. 2:2003;407-411.
75. Ogris M., Steinlein P., Kursa M., Mechtler K., Kircheis R., Wagner E. The size of DNA/transferrin-PEI complexes is an important factor for gene expression in cultured cells. Gene Ther. 5:1998;1425-1433.
76. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. 92:1995;7297-7301.
77. Greber U.F., Willetts M., Webster P., Helenius A. Stepwise dismantling of adenovirus 2 during entry into cells. Cell. 75:1993;477-486.
78. Leopold P.L., Ferris B., Grinberg I., Worgall S., Hackett N.R., Crystal R.G. Fluorescent virions: dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells. Hum. Gene Ther. 9:1998;367-378.
79. Davison E., Kirby I., Whitehouse J., Hart I., Marshall J.F., Santis G. Adenovirus type 5 uptake by lung adenocarcinoma cells in culture correlates with Ad5 fibre binding is mediated by alpha(v)β1 integrin and can be modulated by changes in β1 integrin function. J. Gene Med. 3:2001;550-559.
80. McDonald D., Stockwin L., Matzow T., Blair Zajdel M.E., Blair G.E. Coxackie and adenovirus receptor (CAR)-dependent and major histocompatibility complex (MHC) class I-independent uptake of recombinant adenoviruses into human tumour cells. Gene Ther. 6:2001;1512-1519.
81. Miyazawa N., Leopold P.L., Hackett N.R., Ferris B., Worgall S., Falck-Pedersen E., Crystal R.G. Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors. J. Virol. 73:1999;6056-6065.
82. Fasbender A., Zabner J., Chillòn M., Moninger T.O., Puga A.P., Davidson B.L., Welsh M.J. Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J. Biol. Chem. 272:1997;6479-6489.
83. Selbo P.K., Sivam G., Fodstad Ø., Sandvig K., Berg K. In vivo documentation of photochemical internalization, a novel approach to site specific cancer therapy. Int. J. Cancer. 92:2001;761-766.
84. Korbelik M., Dougherty G.J. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res. 59:1999;1941-1946.
85. Schulz I., Mahler H.C., Boiteux S., Epe B. Oxidative DNA base damage induced by singlet oxygen and photosensitization: recognition by repair endonucleases and mutagenicity. Mutat. Res. 16:2000;145-156.
86. Evans H.H., Horng M.F., Ricanati M., Deahl J.T., Oleinick N.L. Mutagenicitiy of photodynamic therapy as compared to UVC and ionizing radiation in human and murine lymphoblast cell lines. Photochem. Photobiol. 66:1997;690-696.
87. Fischer P.M., Krausz E., Lane D.P. Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation. Bioconjug. Chem. 12:2001;825-841.
88. Lindgren M., Hallbrink M., Prochiantz A., Langel U. Cell-penetrating peptides. Trends Pharmacol. Sci. 21:2000;99-103.
89. Plank C., Zauner W., Wagner E. Application of membrane-active peptides for drug and gene delivery across cellular membranes. Adv. Drug Deliv. Rev. 34:1998;21-35.
90. Berg K., Moan J. Optimization of wavelengths in photodynamic therapy. Moser J.G. Photodynamic Tumor Therapy, 2nd and 3rd Generation Photosensitizers. 1998;151-168 Harwood Academic Publishers, London.
91. Moan J., Berg K., Iani V. Action spectra of dyes relevant for photodymanic therapy. Moser J.G. Photodynamic Tumor Therapy, 2nd and 3rd Generation Photosensitizers. 1998;169-181 Harwood Academic Publishers, London.
92. Rockson S.G., Lorenz D.P., Cheong W.-F., Woodburn K.W. An emerging clinical cardiovascular role for photodynamic therapy. Circulation. 102:2000;591-596.
93. Yamaguchi A., Woodburn K.W., Hayase M., Robbins R.C. Reduction of vein graft disease using photodynamic therapy with motexafin lutetium in a rodent isograft model. Circulation. 102(suppl. III):2000;III-275-III-280.
94. Folini M., Berg K., Millo E., Villa R., Prasmickaite L., Daidone M.G., Benatti U., Zaffaroni N. Photochemical internalization of a peptide nucleic acid targeting the catalytic subunit of human telomerase. Cancer Res. 63:2003;3490-3494.
95. Bonsted A., Engesæter B.Ø., Høgset A., Mælandsmo G.M., Prasmickaite L., Kaalhus O., Berg K. Transgene expression is increased by photochemically mediated transduction of polycation-complexed adenoviruses. Gene Ther. 2003;. in press.